Postnatal Corticosteroids for Bronchopulmonary Dysplasia

Clinics in Perinatology

Volumn 36, Issue 1, 2009, Pages 177-188

  Jobe, Alan H ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Alveoli; Lung injury; Mechanical ventilation; Neurodevelopment; Premature

Indexed keywords

BETAMETHASONE; BETAMETHASONE SODIUM PHOSPHATE; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; HYDROCORTISONE; INDOMETACIN; PLACEBO; PREDNISOLONE;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTENSION; LOW BIRTH WEIGHT; LUNG DYSPLASIA; LUNG FUNCTION; NERVE CELL DIFFERENTIATION; NONHUMAN; POSTNATAL CARE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BRONCHOPULMONARY DYSPLASIA; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; LUNG;

EID: 58249141349     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2008.09.016     Document Type: Review

References (53)

1. Walsh M.C., Yao Q., Horbar J.D., et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 118 (2006) e1328-e1335
2. American Academy of Pediatrics - American Academy of Pediatrics Committee on Fetus and Newborn and Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002) 330-338
3. Finer N.N., Powers R.J., Ou C.H., et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 117 (2006) 704-713
4. Stark A.R., Carlo W.A., Tyson J.E., et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 344 (2001) 95-101
5. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114 (2004) 1649-1657
6. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (2003) CD001144
7. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev (2003) CD001145
8. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (2003) CD001146
9. Doyle L.W., Davis P.G., Morley C.J., et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 117 (2006) 75-83
10. Bhandari A., Schramm C.M., Kimble C., et al. Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. Pediatrics 121 (2008) e344-e349
11. Watterberg K.L., Demers L.M., Scott S.M., et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97 (1996) 210-215
12. Andrews W.W., Goldenberg R.L., Faye-Petersen O., et al. The Alabama Preterm Birth Study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23- to 32-week preterm newborn infants. Am J Obstet Gynecol 195 (2006) 803-808
13. Coalson J.J. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 8 (2003) 73-81
14. De Dooy J., Colpaert C., Schuerwegh A., et al. Relationship between histologic chorioamnionitis and early inflammatory variables in blood, tracheal aspirates, and endotracheal colonization in preterm infants. Pediatr Res 54 (2003) 113-119
15. Speer C.P. Inflammation and bronchopulmonary dysplasia. Semin Neonatol 8 (2003) 29-38
16. Schmidt B., Roberts R.S., Fanaroff A., et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 148 (2006) 730-734
17. Watterberg K.L. Adrenocortical function and dysfunction in the fetus and neonate. Semin Neonatol 9 (2004) 13-21
18. Durand M., Mendoza M.E., Tantivit P., et al. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 109 (2002) 262-268
19. Buttgereit F., Brand M.D., and Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 58 (1999) 363-368
20. Lee B.H., Stoll B.J., McDonald S.A., et al. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 121 (2008) 289-296
21. Karemaker R., Heijnen C.J., Veen S., et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res 60 (2006) 745-750
22. Shah S.S., Ohlsson A., Halliday H., et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev (2003) CD002057
23. Cole C.H., Colton T., Shah B.L., et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. [see comments]. N Engl J Med 340 (1999) 1005-1010
24. Dubus J.C., Montharu J., Vecellio L., et al. Lung deposition of HFA beclomethasone dipropionate in an animal model of bronchopulmonary dysplasia. Pediatr Res 61 (2007) 21-25
25. Watterberg K.L., Scott S.M., and Naeye R.L. Chorioamnionitis, cortisol, and acute lung disease in very low birth weight infants. Pediatrics 99 (1997) E6
26. Jobe A.H., and Ikegami M. Fetal responses to glucocorticoids. In: Mendelson C.R. (Ed). Endocrinology of the lung (2000), Humana Press, Totowa (NJ) 45-57
27. Kamphuis P.J., de Vries W.B., Bakker J.M., et al. Reduced life expectancy in rats after neonatal dexamethasone treatment. Pediatr Res 61 (2007) 72-76
28. Liu Y., Havinga R., Bloks V.W., et al. Postnatal treatment with dexamethasone perturbs hepatic and cardiac energy metabolism and is associated with a sustained atherogenic plasma lipid profile in suckling rats. Pediatr Res 61 (2007) 165-170
29. Wintour E.M., Moritz K.M., Johnson K., et al. Reduced nephron number in adult sheep, hypertensive as a result of prenatal glucocorticoid treatment. J Physiol 549 (2003) 929-935
30. Ikegami M., Jobe A.H., Newnham J., et al. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med 156 (1997) 178-184
31. Marlow N., Hennessy E.M., Bracewell M.A., et al. Motor and executive function at 6 years of age after extremely preterm birth. Pediatrics 120 (2007) 793-804
32. Short E.J., Klein N.K., Lewis B.A., et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 112 (2003) e359
33. Ehrenkranz R.A., Walsh M.C., Vohr B.R., et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116 (2005) 1353-1360
34. Inder T.E., Warfield S.K., Wang H., et al. Abnormal cerebral structure is present at term in premature infants. Pediatrics 115 (2005) 286-294
35. Constable R.T., Ment L.R., Vohr B.R., et al. Prematurely born children demonstrate white matter microstructural differences at 12 years of age, relative to term control subjects: an investigation of group and gender effects. Pediatrics 121 (2008) 306-316
36. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 1 (2001) 1
37. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350 (2004) 1304-1313
38. Murphy B.P., Inder T.E., Huppi P.S., et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 107 (2001) 217-221
39. LeFlore J.L., Salhab W.A., Broyles R.S., et al. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. Pediatrics 110 (2002) 275-279
40. Parikh N.A., Lasky R.E., Kennedy K.A., et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 119 (2007) 265-272
41. O'Shea T.M., Kothadia J.M., Klinepeter K.L., et al. Randomized placebo-controlled trial of a 42 day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1 year adjusted age. Pediatrics 104 (1999) 15-27
42. O'Shea T.M., Washburn L.K., Nixon P.A., et al. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 120 (2007) 594-602
43. Nixon P.A., Washburn L.K., Schechter M.S., et al. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. J Pediatr 150 (2007) 345-350
44. Washburn L.K., Nixon P.A., and O'Shea T.M. Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. Pediatrics 118 (2006) 1592-1599
45. Gross S.J., Anbar R.D., and Mettelman B.B. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 115 (2005) 681-687
46. Wilson T.T., Waters L., Patterson C.C., et al. Neurodevelopmental and respiratory follow-up results at 7 years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics 117 (2006) 2196-2205
47. Doyle L.W., Davis P.G., Morley C.J., et al. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 119 (2007) 716-721
48. Watterberg K.L., Shaffer M.L., Mishefske M.J., et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 120 (2007) 40-48
49. Rademaker K.J., Uiterwaal C.S., Groenendaal F., et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 150 (2007) 351-357
50. Lodygensky G.A., Rademaker K., Zimine S., et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 116 (2005) 1-7
51. Karemaker R., Kavelaars A., ter Wolbeek M., et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 121 (2008) e870-e878
52. Shinwell E.S., Lerner-Geva L., Lusky A., et al. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 92 (2007) F30-F33
53. Doyle L.W., Halliday H.L., Ehrenkranz R.A., et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 115 (2005) 655-661